EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

D. DIMER LEVEL IN MULTIPLE MYELOMA PATIENTS PRE AND POST TREATMENT

Hiba Habeb Alla Mohammed Hussein* and Hiba Khalil

ABSTRACT

Background: Thromboembolism is relatively common and serious event in individuals with malignancy and different type of cancer. Patients with Multiple Myeloma are at higher risk for venous thromboembolism with reported incidences of this complication being up to 30% especially in patients receiving multi agent chemotherapy and anti-angiogenic drugs. This study aimed to evaluate (D. dimer) level among Multiple Myeloma Patients pre and post thalidomide treatment, in Khartoum state -Sudan. Materials and Methods: The selection criteria of Sudanese MM patients depend on CBC results, bone marrow examination and hemoglobin electrophoresis. While exclusion criteria include Inflammatory, hypertension and DM to avoid the false positive results .Blood samples from 30 Sudanese MM patients were collected before and after one month of thalidomide treatment .The treatment protocol is thalidomide admitted 100mg/OD, Dexamethasone 40mg every week and Aspirin 100mg/day. 67% were males and 33%were females, with mean age was 44 years. The D. dimer level was measured by I ChromaTM. based on immunoassay principle. Data were analyzed by using statistical package for the social science (SPSS) version 21. Results and Conclusion: Our study revealed statistically significant difference of D. dimer level before and after administration of thalidomide treatment. The mean of D. dimer level among Sudanese patients of MM after treatment (1293.96 ng/ml ±928.45) was significantly higher than the level before treatment (478.85ng/ml ±317.37), (P. value 0.001). D. dimer level should be considered as follow up test before and after treatment to monitor the prognostic situation of the patient from the risk of thrombosis.

Keywords: Multiple Myeloma, D. dimer, Sudan.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 March 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: MARCH ISSUE PUBLISHED

    MARCH 2024 issue has been successfully launched on MARCH 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia